



9 March 2026

cyclomedica
technegas

The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000

Cyclopharm Ltd
ABN 74 116 931 250
Unit 4, 1 The Crescent
Kingsgrove NSW 2208 Australia
T 61 2 9541 0411
F 61 2 9543 0960
www.cyclopharm.com.au

Results of CYC Share Purchase Plan

Cyclopharm Limited (ASX:CYC) advises that its Share Purchase Plan (SPP) has closed, raising approximately \$182,500 from eligible shareholders.

A total of 192,097 new fully paid CYC ordinary shares (SPP Shares) will be issued to successful applicants at an issue price of \$0.95 per SPP Share.

The SPP was offered to 2,200 eligible shareholders. The SPP provided shareholders with the opportunity to participate in Cyclopharm's recent capital raising on the same terms as institutional and sophisticated investors.

The Company notes that the SPP was conducted during a period of challenging equity market conditions and heightened global uncertainty, which has impacted capital markets more broadly.

Cyclopharm's Managing Director, James McBrayer said: "We appreciate the support of those shareholders who elected to participate in the SPP during what continues to be a challenging market environment."

The new shares are expected to be allotted on 12 March 2026 and quoted on ASX on 13 March 2026. Any refunds for applications where relevant are expected to be made as soon as practicable after the New Shares are issued. SPP Shares will rank equally with existing fully paid CYC ordinary shares from their date of issue.

This ASX announcement was authorised for release by James McBrayer, Managing Director, CEO and Company Secretary

For more information, please contact:

Mr James McBrayer
Managing Director, CEO and Company Secretary
Cyclopharm Limited
T: +61 (02) 9541 0411

Cyclopharm Limited

Cyclopharm is an ASX-listed radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas used in functional lung ventilation imaging.

Technegas®

The Technegas technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro-furnaced for a few seconds at around 2,700 °C. The resultant gas-like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. Historically used in the diagnosis of pulmonary embolism, Technegas, together with advancements in complementary technology, multimodality imaging, and analytical software, is being utilised in other disease states, including COPD, asthma, pulmonary hypertension, and certain interventional applications, such as lobectomies in lung cancer and lung volume reduction surgery.